Molecular Mechanisms of microRNA-494 Involving in Cerebral Ischemia

NCT ID: NCT03577093

Last Updated: 2018-07-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-06-06

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We and other investigations suggested that the activation of nerve cell cycle following cerebral ischemia led to neuronal apoptosis, glial cell proliferation and the formation of glial scar.The cyclin-dependent kinases (CDKs) and cyclins jointly promoted the cell cycle progression. Our preliminary clinical trial found a new microRNA-miR-494, which involved in the occurrence of acute ischemic stroke. In our animal experiment, miR-494 could relieve cerebral ischemia injury through inhibiting cyclin-dependent kinase 6(CDK6), ubiquitin-conjugating enzyme E2L6 (UBE2L6) and histone deacetylase 3 (HDAC3), which suggested that miR-494 might play an important role in the regulation of cell cycle following cerebral ischemia. This project intends to verify the following hypothesis:①miR-494 suppresses CDK6, and/or fibroblast growth factor16(FGF16)-Ras-extracellular signal-regulated kinase(ERK)--v-myc avian myelocytomatosis viral oncogene homolog(MYC) pathway, and/or phosphatase and tensin homolog(PTEN)-/protein kinase B(AKT)-mechanistic target of rapamycin(mTOR)-S6k pathway;②miR-494 inhibits UBE2L6, upregulates the hypoxia-inducible factor 1 α(HIF-1α) expression in nerve cells, thereby increases the p21 and p27 protein levels and inhibits cyclin-dependent kinase2(CDK2)activity;③miR-494 represses HDAC3 and downregulates the cyclin-dependent kinase1(CDK1)protein level. These all mediate the cell cycle arrest of neurons and astrocytes, reduce the neuronal apoptosis and glial scar formation,promote the recovery of neurological function and provide new targets for the treatment of ischemic stroke.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ischemic stroke

acute ischemic stroke patients within 6h after stroke onset

There is no intervention at all.

Intervention Type OTHER

There is no intervention at all.

control

healthy controls

There is no intervention at all.

Intervention Type OTHER

There is no intervention at all.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

There is no intervention at all.

There is no intervention at all.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* (1)diagnosis of first ischemic stroke based on clinical information and magnetic resonance imaging; (2)presentation of subjects within 6h of the event; (3)National Institutes of Health Stroke Scale (NIHSS) score between 4 and 15.

Exclusion Criteria

* (1)suspected cardiogenic embolism;(2)secondary stroke from cerebral hemorrhage, trauma, cancer or aneurysm and so on;(3)bleeding tendency;(4)severe cardiac,pulmonary,hepatic or renal insufficiency;(5)Vital signs are unstable to be assessed.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Capital Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ji Xunming,MD,PhD

Vice President of Xuanwu Hospital,Capital Medical University

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Luo Yumin

Role: PRINCIPAL_INVESTIGATOR

Capital Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Xuanwu Hospital

Beijing, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Luo Yumin

Role: CONTACT

01083198129

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Luo Yumin

Role: primary

01083198129

References

Explore related publications, articles, or registry entries linked to this study.

Bizen N, Inoue T, Shimizu T, Tabu K, Kagawa T, Taga T. A growth-promoting signaling component cyclin D1 in neural stem cells has antiastrogliogenic function to execute self-renewal. Stem Cells. 2014 Jun;32(6):1602-15. doi: 10.1002/stem.1613.

Reference Type BACKGROUND
PMID: 24302516 (View on PubMed)

Zhao H, Wang J, Gao L, Wang R, Liu X, Gao Z, Tao Z, Xu C, Song J, Ji X, Luo Y. MiRNA-424 protects against permanent focal cerebral ischemia injury in mice involving suppressing microglia activation. Stroke. 2013 Jun;44(6):1706-13. doi: 10.1161/STROKEAHA.111.000504. Epub 2013 Apr 23.

Reference Type BACKGROUND
PMID: 23613494 (View on PubMed)

Iyirhiaro GO, Zhang Y, Estey C, O'Hare MJ, Safarpour F, Parsanejad M, Wang S, Abdel-Messih E, Callaghan SM, During MJ, Slack RS, Park DS. Regulation of ischemic neuronal death by E2F4-p130 protein complexes. J Biol Chem. 2014 Jun 27;289(26):18202-13. doi: 10.1074/jbc.M114.574145. Epub 2014 May 14.

Reference Type RESULT
PMID: 24828495 (View on PubMed)

Nobs L, Baranek C, Nestel S, Kulik A, Kapfhammer J, Nitsch C, Atanasoski S. Stage-specific requirement for cyclin D1 in glial progenitor cells of the cerebral cortex. Glia. 2014 May;62(5):829-39. doi: 10.1002/glia.22646. Epub 2014 Feb 19.

Reference Type RESULT
PMID: 24550001 (View on PubMed)

Demyanenko S, Uzdensky A. Profiling of Signaling Proteins in Penumbra After Focal Photothrombotic Infarct in the Rat Brain Cortex. Mol Neurobiol. 2017 Nov;54(9):6839-6856. doi: 10.1007/s12035-016-0191-x. Epub 2016 Oct 22.

Reference Type RESULT
PMID: 27771897 (View on PubMed)

Zhao H, Luo Y, Liu X, Wang R, Yan F, Liu X, Li S, Leak RK, Ji X. Ischemic post-conditioning partially reverses cell cycle reactivity following ischemia/reperfusion injury: a genome-wide survey. CNS Neurol Disord Drug Targets. 2013 May 1;12(3):350-9. doi: 10.2174/1871527311312030008.

Reference Type RESULT
PMID: 23469856 (View on PubMed)

Liu L, Lu Y, Martinez J, Bi Y, Lian G, Wang T, Milasta S, Wang J, Yang M, Liu G, Green DR, Wang R. Proinflammatory signal suppresses proliferation and shifts macrophage metabolism from Myc-dependent to HIF1alpha-dependent. Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):1564-9. doi: 10.1073/pnas.1518000113. Epub 2016 Jan 25.

Reference Type RESULT
PMID: 26811453 (View on PubMed)

Fournier M, Orpinell M, Grauffel C, Scheer E, Garnier JM, Ye T, Chavant V, Joint M, Esashi F, Dejaegere A, Gonczy P, Tora L. KAT2A/KAT2B-targeted acetylome reveals a role for PLK4 acetylation in preventing centrosome amplification. Nat Commun. 2016 Oct 31;7:13227. doi: 10.1038/ncomms13227.

Reference Type RESULT
PMID: 27796307 (View on PubMed)

Jiang Y, Hsieh J. HDAC3 controls gap 2/mitosis progression in adult neural stem/progenitor cells by regulating CDK1 levels. Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13541-6. doi: 10.1073/pnas.1411939111. Epub 2014 Aug 26.

Reference Type RESULT
PMID: 25161285 (View on PubMed)

Li G, Ma X, Zhao H, Fan J, Liu T, Luo Y, Guo Y. Long non-coding RNA H19 promotes leukocyte inflammation in ischemic stroke by targeting the miR-29b/C1QTNF6 axis. CNS Neurosci Ther. 2022 Jun;28(6):953-963. doi: 10.1111/cns.13829. Epub 2022 Mar 24.

Reference Type DERIVED
PMID: 35322553 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

miR-494

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.